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Background: Prolonged P wave duration is a marker of delayed inter-atrial conduction which may predict
cardiovascular disease (CVD). Type 2 diabetes is a risk factor for all atherosclerotic manifestations including stroke.
We evaluated the prognostic significance of prolonged P wave duration among middle-aged Finnish type 2 diabetes
patients with and without prevalent non-major macrovascular disease (PNMMVD) with respect to total and stroke
mortality.
Methods: We followed up for 18 years 739 type 2 diabetic patients without previous major CVD event at baseline.
Participants were stratified according to P wave duration (<114 or ≥114 ms) and PNMMVD (i.e. coronary heart disease
defined as ischaemic ECG changes and typical symptoms of angina pectoris, or claudication; yes or no). The Cox
proportional hazards model was used to estimate the joint association between P wave duration, PNMMVD and the
mortality risk.
Results: During the follow-up, 509 patients died, and 59 of them died from stroke. Those who had prolonged P wave
duration had 2.45 (95% confidence interval: 1.11-5.37) increased stroke mortality among PNMMVD patients. In patients
without PNMMVD, there was no relationship between P wave duration and stroke mortality.
Conclusions: As an easily measurable factor P wave duration merits further studies with higher number of patients to
evaluate its importance in the estimation of stroke risk in type 2 diabetic patients with PNMMVD.
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P wave duration is a marker of atrial conduction derived
from standard electrocardiogram (ECG). Prolonged P
wave duration has been suggested to be an easily measur-
able risk factor for underlying subclinical heart disease [1].
In fact, it has been associated with atrial fibrillation (AF)
and also more recently with increased all-cause, cardiovas-
cular disease (CVD) and stroke mortality among general
population [1-4]. Prolonged P wave duration is also associ-
ated with diabetes [1].
In patients with type 2 diabetes, atherosclerosis is more
common and the mortality is higher after cardiovascular
events such as acute myocardial infarction (MI), stroke, or* Correspondence: tkveps@utu.fi
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article, unless otherwise stated.lower extremity amputation due to peripheral vascular
disease [5] than in their non-diabetic counterparts. To our
knowledge there are no previous long-term studies
studying the association between P wave duration and
stroke mortality among type 2 diabetes patients, espe-
cially among diabetes patients with high risk for CVD
events. Therefore, we decided to evaluate the prognostic
significance of prolonged P wave duration with respect to
stroke mortality among middle-aged type 2 diabetes pa-
tients with or without signs of non-major macrovascular
disease (coronary heart disease without myocardial infarc-
tion, or claudication). We contemplated that patients hav-
ing signs of non-major macrovascular disease are in high
risk of developing major CVD events and aimed to exam-
ine whether among these patients prolonged P wave dur-
ation would identify those who are in particularly high
risk for stroke mortality.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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A detailed description of the study participants has been
published previously [6]. Briefly, 1059 subjects (581 men,
478 women) with type 2 diabetes, aged 45–64 years, born
and living in the Turku University Hospital district in
West Finland or in the Kuopio University Hospital district
in East Finland were identified through a national drug re-
imbursement register. Patients with type 1 diabetes, based
on early onset diabetes, history of ketoacidosis and low
glucagon-stimulated C-peptide measurement at baseline,
were excluded.
We excluded from all statistical analyses a total of 320
subjects. Exclusion criteria were major previous CVD
event (possible or definite stroke, possible or definite MI
or lower-extremity amputation) (n = 252) or missing ECG
data (n = 108) or known AF (n = 23). Thus, the final study
population comprised 739 patients with type 2 diabetes
(381 men, 358 women).
Baseline study
The baseline examination was carried out between 1982
and 1984 during one outpatient visit at the Clinical Re-
search Unit of the University of Kuopio or the Rehabilita-
tion Research Centre of the Social Insurance Institution in
Turku. The visit included an interview to determine his-
tory of smoking, alcohol intake, physical activity, use of
medication and history of chest pain suggestive of cor-
onary heart disease (CHD). The examinations and the
methods used have been described previously in detail [6].
On all participants at baseline a standard 12-lead resting
ECG was performed at 8–9 o’clock AM. Before recording
the subject had fasted for 12 hours. ECG abnormalities
were recorded according to the Minnesota code, including
left ventricular hypertrophy (LVH). The coder of the ECGs
was blinded to the glucose tolerance status and other in-
formation on the study subjects. The ischemic changes by
ECG (The Whitehall criteria) included Minnesota codes
1.1-1.3, 4.1-4.3, 5.1-5.3, 7.1 [7]. In addition, a three-
dimensional computerized ECG recording was performed.
Measurements for atrial conduction were based on the
Dalhousie ECG Program v. 8.0 [8]. The program was im-
plemented on a SM-4 computer and adapted for use by
the ECG terminals and data communication equipment
(Kone 620, Kone Oy, Finland). P wave duration was mea-
sured from the onset of the P wave to the end of P wave
from the spatial magnitude curve of the X, Y, Z compo-
nents after selective averaging. Computer-identified time
points including P wave onset point were displayed, visu-
ally verified and obvious measurement errors corrected by
one of the authors (M.L.). The Rose classification was
used to evaluate the presence of typical angina pectoris
and intermittent claudication [7]. Prevalent non-major
macrovascular disease (PNMMVD) was defined as coron-
ary heart disease without definite or possible myocardialinfarction (ischaemic ECG changes and typical symptoms
of angina pectoris), or claudication (yes or no).
Medical records of patients who reported that they had
been admitted to hospital for chest pain were reviewed by
two investigators (M.L. and T.R.) after careful standardiza-
tion of the methodology. World Health Organization
(WHO) criteria for verified definite or possible MI based
on chest pain symptoms, ECG changes and determination
of enzyme activities were used to define previous MI [9].
WHO criteria were also used to define previous definite
or possible stroke [10]. Non-traumatic lower extremity
amputations were recorded. Blood pressure was measured
with the person in the sitting position after a 5-min rest.
Body mass index (BMI) was calculated by dividing
weight in kilograms divided by the square of height in
meters. Hypertension was defined as systolic blood pres-
sure ≥160 mmHg, or diastolic pressure ≥95 mmHg, or an-
tihypertensive drug treatment.
Biochemical methods
After 12-h fast, blood was collected at 08.00. Glycosylated
haemoglobin (HbA1) level (reference range in non-
diabetic subjects 5.5–8.5%) was determined by affinity
chromatography (Isolab, Akron, OH, USA). Levels of
serum total cholesterol, HDL cholesterol and triglycerides
were determined using standard laboratory methods [6].
Coomassie brilliant blue was used to measure total urinary
protein concentration from a morning spot urine speci-
men [11]. The interassay coefficient of variation was in
this study was 7% at protein levels of 100 and 250 mg/L
and 3% at 600 mg/L.
Follow-up study
Follow-up continued for 18 years until 1 January 2001. In-
formation on vital status of all participants and copies of
death certificates of subjects who had died before the end
of follow-up were obtained from the national Cause-of-
Death Register (Statistics Finland). All death certificates of
participants were reviewed by two of the authors (A.J. and
S.L.). In the final classification of causes of death, hospital
records and autopsy records were also reviewed if avail-
able. The study endpoints were total mortality, CVD mor-
tality [International Classification of Diseases 9th revision
(ICD-9) codes 390–459], CHD mortality (ICD-9 codes
410–414) and stroke mortality (ICD-9 codes 431–438).
The Ethics Committees of the Turku University and
Turku University Central Hospital, and the University of
Kuopio approved the study. Informed written consent
was obtained from all participants.
Statistical analyses
All statistical analyses were performed using PASW statis-
tics (version 18.0; SPSS Inc., Chicago, IL, USA). Data for
continuous variables are expressed as mean ± SD or
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percentage. Baseline characteristics were compared using
analysis of variance for continuous variables and the chi-
square test for categorical variables. Because of a skewed
distribution, total triglycerides and urinary protein was
analysed after logarithmic transformation.
There is still controversy for the cut off level for pro-
longed P wave duration [12,13]. Various cut off values
have been suggested for prolonged P wave duration, such
as 110 ms or 120 ms, where most of the recommendations
are based on earlier textbooks and other publications that
often did not involve original work [12,13]. Therefore, we
have made analyses using several cut off values for P wave
duration, 104 ms, 108 ms, 110 ms, 114 ms and 120 ms
(corresponding to 50, 60, 70, 80 and 90 percentiles of the
distribution) to find out a threshold of P wave duration as-
sociated with a steep increase in mortality. Death rates/
1000 patient years according to 50, 60, 70, 80 and 90 per-
centiles of P wave duration were as follows; for total mor-
tality: 58.9, 59.6, 60.6, 64.7, 75.4, and for stroke mortality:
6.7, 7.7, 8.1, 9.1 and 11.6. For lower percentiles mortality
risk increases relatively smoothly but after 80th percentile
the risk increased more rapidly. Therefore we decided to
use the 80 percentile cut off value to categorize partici-
pants according to P wave duration into two groups;
normal or prolonged (<114 ms or ≥114 ms). This cut
off value for P wave duration was used to calculate haz-
ard ratios for mortality among patients with and with-
out PNMMVD.
We used the Cox proportional hazards model to evalu-
ate the association of prolonged P wave duration among
patients with or without PNMMVD on total, CVD and
stroke mortality with P wave duration <114 ms as the ref-
erence. Unadjusted and adjusted hazard ratios and their
95% confidence intervals were calculated. Adjustment was
made for age, sex, duration of diabetes, area of residence
(East or West Finland), total cholesterol, use of alcohol
(user vs. non-user), smoking (smoker vs. non-smoker),
HDL cholesterol, total triglycerides (log), urinary protein
(log), HbA1, diabetes medication (diet alone, oral drugs,
insulin), physical activity, hypertension, BMI, heart rate
and LVH. Kaplan–Meier procedure was used to evaluate
the associations between P wave duration and stroke mor-
tality in participants with and without PNMMVD. There
were no interactions in Cox proportional hazards model
between sex and P wave duration or sex and PNMMVD
with respect to mortality. Therefore, men and women
were combined in all statistical analyses. P < 0.05 was con-
sidered to be statistically significant.
Results
PNMMVD stratification was made because we observed
that total and stroke mortality was significantly increased
among patients with PNMMVD: 76.8% (322 out of 419)of patients with PNMMVD and 58.4% (187 out of 320)
of patients without PNMMVD died during follow-up
(P <0.001 log rank). The corresponding figures for
stroke mortality were 9.1% (38 out of 419) and 6.6% (21
out of 320), respectively (p = 0.02 log rank).
We observed interaction between P wave duration
114 ms (= 80th percentile) and PNMMVD with respect
to stroke mortality.
The clinical and laboratory characteristics of the partici-
pants at baseline according to P wave duration are pre-
sented in Table 1. Prolonged P wave duration at baseline
was associated with male gender, increased age, triglycer-
ides, BMI, increased urinary protein. Prolonged P wave
duration was also associated with higher prevalence of
hypertension and PNMMVD. A total of 16.1% of the sub-
jects had prolonged P wave duration ≥114 ms and
PNMMVD, 6.9% had P wave ≥114 ms, but no PNMMVD.
40.6% had P wave <114 ms and PNMMVD, and further-
more 36.4% had P wave <114 ms and no PNMMVD.
PNMMVD patients’ median P wave duration was 106 ms
(25th percentile: 96 ms, 75th percentile: 110 ms), mini-
mum 62 ms and maximum 174 ms. Patients without
PNMMVD had median P wave duration of 104 ms (25th
percentile: 98 ms, 75th percentile: 114 ms), minimum 70
ms, maximum 135 ms.
Outcome according to P wave duration and PNMMVD
During 9,185 patient-years of follow-up a total of 509
(68.9%) patients died, 329 (44.5%) died from CVD and 59
(8.0%) died from stroke. Among the participants without
prolongation of the P wave duration, 221 out of 300 with
PNMMVD died (144 from CVD and 22 from stroke) and
160 out of 269 participants without PNMMVD died (99
from CVD and 19 from stroke). Among the participants
with prolongation of the P wave duration, 101 out of 119
with PNMMVD died (72 from CVD and 16 from stroke)
and 27 out of 51 participants without PNMMVD died (14
from CVD and 2 from stroke). The event rates of total,
CVD and stroke mortality per person years according P
wave duration in patients with or without PNMMVD are
shown in Figure 1.
Among PNMMVD patients those who had prolonged P
wave duration had significantly an increased risk for total,
CVD and stroke mortality in univariate analysis. This
trend was also seen in multivariate analysis, but the associ-
ation was significant only for stroke mortality. The relative
risk for stroke mortality among PNMMVD patients with
prolonged P wave duration was 2.25-fold (CI 1.18-4.31)
increased in univariate and 2.45-fold (CI 1.11-5.37) in-
creased in multivariate analysis when compared to pa-
tients with normal P wave duration (Table 2). Among
patients without PNMMVD prolonged P wave duration
was not associated with increase in total, CVD or stroke
mortality. In fact prolonged P wave duration with respect
Table 1 Baseline clinical and laboratory characteristics
and the number of subjects with various outcomes
according to P wave duration among type 2 diabetes
patients
P wave duration
Variables <114 ms ≥114 ms P
N 569 170
Age (years) 57.5 ± 5.29 59.0 ± 4.21 0.001
Duration of diabetes (years) 7.9 ± 3.9 8.0 ± 3.9 0.649
Total cholesterol, mmol/L 6.68 ± 1.66 6.81 ± 1.98 0.381
HDL cholesterol, mmol/L 1.25 ± 0.363 1.19 ± 0.310 0.051
Triglycerides, mmol/L 2.38 ± 2.58 3.10 ± 4.08 0.006
Glycosylated hemoglobin A1, % 9.90 ± 2.39 10.1 ± 1.93 0.257
BMI, kg/m2 29.0 ± 5.23 30.2 ± 5.13 0.007
Urinary protein, mg/L 220 ± 445 396 ± 879 0.001
Physical activity, MET† 4.1 ± 1.9 3.85 ± 1.8 0.091
Heart rate, bpm 74 ± 13 75 ± 15 0.368
Women, % 50.6 41.2 0.031
Current smokers, % 16.7 17.6 0.772
Hypertension/-medication, % 56.6 74.7 <0.001
Systolic BP, mmHg 153 ± 23 157 ± 23 0.036
Diastolic BP, mmHg 85 ± 12 88 ± 12 0.005
Alcohol users, % 35.9 43.5 0.070
Area of residence, Turku, % 51.8 48.8 0.489
LVH, % 12.3 16.5 0.160
PNMMVD*, % 52.7 70.0 <0.001
Diabetes treatment 0.823
diet only, % 13.5 14.7
oral drugs, % 74.2 71.8
insulin therapy, % 12.3 13.5
Death rates/1000-patient-years
Total mortality 52.9 64.7 0.039
CVD mortality 33.7 43.5 0.070
CHD mortality 24.7 30.3 0.326
Stroke mortality 5.7 9.1 0.153
Data are expressed as the mean ± SD, unless otherwise indicated.
*Prevalent non-major macrovascular disease (ischaemic ECG changes and typical
symptoms of angina pectoris, or claudication), †Metabolic equivalent task.
Figure 1 Total, CVD and stroke mortality according to P wave
duration stratified by prevalent non-major macrovascular disease
(PNMMVD): ○ No PNMMVD with P wave duration ≥114 ms; ● No
PNMMVD with P wave duration <114; □ PNMMVD with P wave
duration <114 ms; ■ PNMMVD with P wave duration ≥114 ms.
Event-rates are expressed per 1000 patient- years of follow-up.
Number of patients without PNMMVD in the two P wave duration
groups (<114 ms and ≥114 ms) were 269 and 51, respectively; the
respective number of patients with PNMMVD were 300 and 119.
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mortality.
The Kaplan-Meier curve (Figure 2) indicates the cumu-
lative survival with respect to stroke mortality for patients
with normal or prolonged P wave duration stratified by
baseline PNMMVD. Patients with PNMMVD and P wave
duration ≥114 ms had poorer prognosis than those with P
wave duration <114 ms. This started to become evident
after four years of follow-up. Among patients without
PNMMVD there was no statistical difference between P
wave duration curves in Kaplan-Meier analysis.Discussion
As far as we know, there are no previous studies aiming
to investigate the predictive value of prolonged P wave
duration on stroke mortality in diabetic subjects with or
without PNMMVD. In our prospective study of middle
aged Finnish type 2 diabetes patients, prolonged P wave
duration was significantly associated with increased
stroke mortality rate among patients with PNMMVD.
This association was independent of conventional CVD
risk factors, proteinuria, duration of diabetes, diabetes
treatment, glycemic control, heart rate and LVH. In pa-
tients without PNMMVD prolonged P wave duration
was not associated with stroke mortality.
P wave duration is a marker of atrial conduction derived
from ECG. Normal P wave can be considered to be less
than 110 ms [12-14]. Prolonged P wave duration signifies
conduction delay between right and left atrium due to im-
pulse slowing or blockage, probably most often but not
exclusively in the Bachmann bundle. On the ECG this
conduction delay is referred to as interatrial block (IAB)
[14-16]. IAB is one of the most common ECG abnormal-
ities but remarkably underdiagnosed [17-20]. The exact
underlying cause for IAB remains relatively unknown.
However, atrial tissue sampling from patients with IAB
consistently shows intercellular fibrotic changes and
intracellular inclusions, particularly in the sarcomere
Table 2 Hazard ratios (P wave ≥114 ms vs. P wave <114 ms) for total mortality, CVD and stroke mortality stratified by
prevalent non-major macrovascular disease (PNMMVD)
HR (95% CI)
Age-adjusted hazard ratios Multivariate-adjusted hazard ratios
Variables P wave ≥114 vs. <114 ms P for interaction P wave ≥114 vs. <114 ms P for interaction
Total mortality
No PNMMVD 0.75 (0.50-1.13) 0.70 (0.45-1.09)
0.020 0.047
PNMMVD 1.31 (1.03-1.66)* 1.18 (0.90-1.54)
CVD mortality
No PNMMVD 0.63 (0.36-1.10) 0.22 (0.27-0.90)*
0.010 0.015
PNMMVD 1.45 (1.09-1.93)* 1.32 (0.95-1.84)
Stroke mortality
No PNMMVD 0.47 (0.11-2.04) 0.36 (0.08-1.66)
0.057 0.089
PNMMVD 2.25 (1.18-4.31)* 2.45 (1.11-5.37)*
*P < 0.05 for the difference between P wave ≥114 vs. <114 ms. Variables in multivariate adjusted: age, sex, area of residence, diabetes duration, total cholesterol,
HDL cholesterol, triglycerides(log), proteinuria(log), smoking, alcohol, HbA1, presence of hypertension, BMI, type of diabetes therapy, physical activity, heart rate
and left ventricular hypertrophy.
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and traditional cardiovascular risk factors, such as hyper-
tension, hypercholesterolemia, smoking, obesity, physical
inactivity and higher age have been associated with IAB
[22]. Similar associations were also seen in our study with
respect to prolonged P wave duration. It is possible that
these CVD risk factors increase P wave duration viaFigure 2 The Kaplan-Meier survival curve for stroke mortality
according to P wave duration stratified by prevalent non-
major macrovascular disease (PNMMVD): ○ No PNMMVD
with P wave duration ≥114 ms (n = 51); ● No PNMMVD with
P wave duration <114 (n = 269); □ PNMMVD with P wave
duration <114 ms (n = 300); ■ PNMMVD with P wave duration
≥114 ms (n = 119). P value denotes the difference between the
survival curves (log rank).endothelial injury, leading to ischemia-induced inter-atrial
conduction delay [22].
Even though our study has limited statistical power be-
cause of the smaller number of patients in the prolonged
P wave groups, there is two possibly inter-related mecha-
nisms suggesting that our findings are likely to be valid
and that these mechanisms could explain the excess
stroke mortality among PNMMVD type 2 diabetes pa-
tients with prolonged P wave duration, i.e. IAB. First, IAB
is associated with left atrial enlargement (LAE) and left
atrium (LA) electromechanical dysfunction [23,24]. In one
study, patients with IAB had lower LA emptying fraction,
lower LA stroke volume and lower LA kinetic energy [24].
The degree of these abnormalities was related to the se-
verity of interatrial conduction delay represented by P
wave duration [24]. These changes in LA could enhance
the risk for thrombosis. In fact, recently it was noticed that
patients who had embolic stroke had significantly higher
prevalence of IAB on the ECG [2,3]. Moreover, in recent
study prolonged P wave duration was also associated with
increased all-cause and CVD mortality [1]. Secondly, IAB
has also been associated with AF [2]. The deterioration of
interatrial conduction in IAB results in a shorter wave-
length and this combined with the probable LAE could in-
crease the number of wavelets in the atrium [25,26].
These mechanisms could enhance the risk that AF would
occur and sustain itself and furthermore increase the
risk for stroke mortality among these patients. In our
study, only patients with PNMMVD had increased stroke
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able that those patients had more advanced coronary
heart disease and therefore, had more severe LA electro-
mechanical dysfunction and were more prone to AF.
It is also possible that independent of an increased risk
for atrial thrombus formation, prolonged P wave duration
is a marker of more advanced atherosclerosis and there-
fore represents patients who more likely have widespread
vascular damage affecting arteries, also in the brain.
Our study has some limitations. It is probable that we
could not exclude from the final analysis all patients who
had previous MI at baseline because more precise imaging
techniques were not available at baseline. Secondly, we
were able to examine only total stroke mortality and not
able to separate between thromboembolic and haemor-
rhagic stroke mortality. In the PNMMVD category we
were not able to include specifically patients with carotid
or cerebrovascular atherosclerosis, however it is plausible
that patients included in this category had already more
general arterial disease and therefore, were also likely to
have carotid or cerebrovascular atherosclerosis. Thirdly,
we had ECG recording and risk factor measurements only
at baseline. Therefore, we have no data on changes in the
P wave duration or other risk factors during the follow-up.
Furthermore, by design of our study, we had only P wave
duration as a marker of atrial conduction. More complete
assessments of the P wave, e.g., P wave dispersion and
amplitude, would provide deeper insight into the associ-
ation between P wave characteristics and mortality among
patients with type 2 diabetes and PNMMVD. Neverthe-
less, and to support our results, recently only P wave dur-
ation has been associated with CVD and stroke mortality
[1-3]. Furthermore, we cannot conclude which ECG lead
would be the most accurate lead to measure P wave dur-
ation. However, it has been suggested that P wave dur-
ation should be measured from all the leads and the lead
giving the longest duration should be used [11]. Our study
results are in accordance with this suggestion.
Finally, at the time of our baseline examination, risk
assessments and interventions for CVD and stroke mor-
tality in type 2 diabetes patients were not routinely per-
formed, in contrast to the situation in clinical practice
today. Diabetes and conventional CVD risk factor con-
trol has become better and procedures to treat acute
cardiac and stroke events have evolved and become
readily available since the baseline study. Therefore, the
prognosis of patients with diabetes and diabetic compli-
cations is probably better than it was some 20 years ago.
Therefore, it is not possible to draw final conclusions on
how strong the association between P wave duration and
stroke mortality is today. Due to these limitations, it is
likely that our study rather underestimates than overesti-
mates the association of P wave duration and PNMMVD
with stroke mortality.Conclusions
Middle-aged type 2 diabetes patients with PNMMVD
and prolonged P wave duration had increased risk for
stroke mortality in our study. Among patients without
PNMMVD, P wave duration was not associated with
stroke mortality. Further studies with higher number of
patients are needed to determine the clinical value of
measuring P wave duration in the estimation of stroke
risk in type 2 diabetic patients with prevalent non-major
macrovascular disease.
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